A global subsidy: Key to affordable drugs for malaria?

Ramanan Laxminarayan, Hellen Gelband

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Abstract

The global fight against malaria has been continually challenged by poor access to affordable, effective medicine. Growing resistance to chloroquine, the traditional treatment, has worsened the situation. Artemisinins, the successor therapy to chloroquine, are at least ten times more costly than the older drug. In developing countries, most malaria medicines are purchased in the private sector, where traditional aid mechanisms do not reach. So a new aid approach was needed. The Affordable Medicines Facility-malaria (AMFm) will efficiently supply publicly subsidized drugs to meet public- and private-sector demand in malaria-endemic countries. If artemisinins are priced more competitively, resistance to them will be delayed.

Original languageEnglish (US)
Pages (from-to)949-961
Number of pages13
JournalHealth Affairs
Volume28
Issue number4
DOIs
StatePublished - Jul 2009

All Science Journal Classification (ASJC) codes

  • General Medicine

Fingerprint

Dive into the research topics of 'A global subsidy: Key to affordable drugs for malaria?'. Together they form a unique fingerprint.

Cite this